Page last updated: 2024-11-05

glycerol 1-stearate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycerol 1-stearate: isolated from the young fronds of the bracken fern Pteridium aquilinum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rac-1-monostearoylglycerol : A rac-1-monoacylglycerol composed of equal amounts of 3-stearoyl-sn-glycerol and 1-stearoyl-sn-glycerol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-monostearoylglycerol : A 1-monoglyceride that has stearoyl as the acyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24699
CHEMBL ID255696
CHEBI ID75555
CHEBI ID75557
SCHEMBL ID4488
MeSH IDM0522764

Synonyms (231)

Synonym
83138-62-9
c21h42o4
.alpha.-monostearin
glycerol .alpha.-monostearate
123-94-4
stearic acid 1-monoglyceride
stearic acid .alpha.-monoglyceride
glycerol 1-stearate
nsc-3875
monostearin (l)
octadecanoic acid,3-dihydroxypropyl ester
tegin
3-stearoyloxy-1,2-propanediol
aldo 75
1-monostearoylglycerol
tegin 515
aldo 33
octadecanoic acid, 2,3-dihydroxypropyl ester
arlacel 165
nsc3875 ,
sandin eu
emerest 2407
glycerin 1-monostearate
glycerin 1-stearate
stearin, 1-mono-
tegin 55g
1-glyceryl stearate
glyceryl 1-monostearate
glycerol 1-monostearate
aldo mslg
1-monostearin
aldo msd
alpha-monostearin
inchi=1/c21h42o4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h20,22-23h,2-19h2,1h
glyceryl stearate
kessco 40
ogeen mav
tegin 503
cerasynt sd
glyceryl monooctadecanoate
stearic monoglyceride
cerasynt wm
drewmulse tp
starfol gms 450
admul
arlacel 169
emcol ca
estol 603
myvaplex 600
monoglyceryl stearate
grocor 5500
starfol gms 900
protachem gms
imwitor 900k
aldo hms
ogeen grb
ai3-00966
stearoylglycerol
sedetine
cerasynt 1000-d
monostearate (glyceride)
lipo gms 600
glycerin monostearate
cefatin
atmos 150
atmul 84
orbon
einecs 250-705-4
aldo-72
emcol msk
aldo-28
hodag gms
emerest 2401
glyceryl monostearate
atmul 67
cyclochem gms
octadecanoic acid, monoester with 1,2,3-propanetriol
arlacel 161
imwitor 191
stearic acid, monoester with glycerol
starfol gms 600
lipo gms 450
ogeen m
ogeen 515
unimate gms
monostearin
emul p.7
dermagine
usaf ke-7
monelgin
citomulgan m
aldo ms
atmul 124
drumulse aa
witconol ms
lipo gms 410
witconol mst
celinhol - a
drewmulse v
cerasynt s
glycerol monostearate
armostat 801
grocor 6000
1,2,3-propanetriol monooctadecanoate
cerasynt se
2,3-dihydroxypropyl octadecanoate
1-octadecanoyl-rac-glycerol
mg(18:0/0:0/0:0)[rac]
LMGL01010003
1-stearoyl-rac-glycerol, >=99%
31566-31-1
glyceryl monostearate (jp17/nf)
D01947
NCGC00164529-01
glycerol alpha-monostearate
einecs 204-664-4
fema no. 2527
(1)-2,3-dihydroxypropyl stearate
glycerol stearate, pure
einecs 245-121-1
nsc 3875
stearic acid alpha-monoglyceride
11099-07-3
octadecanoic acid, ester with 1,2,3-propanetriol
2,3-dihydroxypropyl stearate
S-7950
1-stearoyl-rac-glycerol
cerasynt-sd
glycerol stearate
cutina gms
glycerides, c16-18 mono-
lonzest gms
glyceryl monopalmitostearate
CHEMBL255696
stearin, mono-
monoglycerides, c16-18
cithrol gms 0400
nikkol mgs-a
cremophor gmsk
imwitor 491
chebi:75555 ,
glyceroli monostearas
sorbon mg-100
22610-63-5
1-monostearoyl-rac-glycerol
1-monooctadecanoylglycerol
1-o-octadecanoyl-2n-glycerol
G0085
NCGC00164529-03
NCGC00164529-02
einecs 238-880-5
unii-230ou9xxe4
ec 293-208-8
230ou9xxe4 ,
einecs 293-208-8
dsstox_cid_9160
tox21_301104
NCGC00255004-01
cas-11099-07-3
dsstox_rid_78757
dsstox_gsid_29304
cas-123-94-4
dtxcid909160
dtxsid7029160 ,
NCGC00260122-01
tox21_112160
tox21_202573
rac-glyceryl monostearate
(+-)-2,3-dihydroxypropyl octadecanoate
(+-)-glyceryl monostearate
rac-2,3-dihydroxypropyl octadecanoate
rac-1-monostearoylglycerol
(+-)-1-stearoylglycerol
glycerol 1-octadecanoate
(+-)-1-octadecanoylglycerol
rac-octadecanoylglycerol
CHEBI:75557
1-octadecanoylglycerol
(+-)-1-monostearoylglycerol
glyceryl stearates
abracol s.l.g.
ec 250-705-4
eastman 600
glyceryl monostearate [jan:nf]
FT-0674656
258491e1rz ,
unii-258491e1rz
FT-0626740
FT-0626748
AKOS015901589
rac-glycerol 1-stearate
1-monooctadecanoyl-rac-glycerol
85666-92-8
glyceryl 1-stearate
glyceryl monostearate 40-50
(+/-)-2,3-dihydroxypropyl octadecanoate
glyceryl 1-octadecanoate
SCHEMBL4488
tox21_112160_1
NCGC00164529-04
1-o-stearoylglycerol
octadecanoic acid, 2.3-dihydroxypropyl ester
glycerol .alpha.-sterate
1,2,3-propanetriol 1-octadecanoyl ester
2,3-dihydroxypropyl stearate #
Q-201168
W-110285
(+/-)-2,3-dihydroxypropyl octadecanoate; 1-glyceryl stearate; 1-monooctadecanoylglycerol; 1-monostearin
mfcd00036186
glycerol monostearate, purified
SR-01000944874-1
sr-01000944874
mag 18:0
A903419
Q5572563
glycerol monostearate (gms)
342394-34-7
DB11250
geleol mono and diglycerides
1-stearoyl-rac-glycerol (90per cent)
A890632
BS-50505
1-stearoyl-rac-glycerol (90%)
()-2,3-dihydroxypropyl octadecanoate; 1-glyceryl stearate; 1-monooctadecanoylglycerol; 1-monostearin
glycerol monostearate 40-55
octadecanoic acid, 2,3-dihydroxypropyl ester, (a+/-)-
DTXSID7027968 ,
F71433
celinhol-a
glyceryl stearate (ii)
glyceryl monostearate (ii)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Hemolysis and acute toxicity investigations showed that BU-NLC was safe when given by intravenous injection with reduced toxicity."( The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
He, H; Li, F; Tang, X; Wang, L; Weng, Y; Yang, J, 2010
)
0.36
"The present paper discusses the design, characterization and in vivo evaluation of glyceryl monostearate nanoparticles of Olanzapine, an atypical antipsychotic drug for acute schizophrenia treatment, during which hospitalization is mandatory and adverse effects are at its peak."( Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
Balwani, G; Joseph, E; Reddi, S; Rinwa, V; Saha, R, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" A pharmacokinetic study was conducted in male rats after oral administration of 10 mg kg(-1) VIN in different formulations, it was found that the relative bioavailability of VIN in SLNs was significantly increased compared with that of the VIN solution."( Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability.
Chen, D; Luo, Y; Qin, J; Ren, L; Zhao, X, 2006
)
0.33
"Nitrendipine is an antihypertensive drug with poor oral bioavailability ranging from 10 to 20% due to the first pass metabolism."( Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
Chandrasekar, D; Diwan, PV; Kishan, V; Kumar, VV; Ramakrishna, S; Rao, YM, 2007
)
0.34
"Oral drug development had been hindered by the bioavailability issue despite vast market popularity."( Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells.
Jia, JX; Wasan, KM, 2008
)
0.35
" The relative bioavailability of QT-SLNs to quercetin suspension was 571."( Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Li, H; Li, L; Lou, H; Ma, Y; Zhai, G; Zhao, X, 2009
)
0.35
" Absolute bioavailability of theophylline was 96% and 46% for the formulations containing PEG 6000 and glycerol monostearate, respectively."( In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
Gascón, AR; Hernández, RM; Igartua, M; Ochoa, L; Pedraz, JL; Solinís, MA, 2010
)
0.36
"Apomorphine, a dopamine receptor agonist for treating Parkinson's disease, has very poor oral bioavailability (<2%) due to the first-pass effect."( Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations.
Fang, JY; Fu, YS; Huang, YB; Kao, YR; Tsai, MJ; Tsai, YH; Wu, PC, 2011
)
0.37
" The objective of this research work was to study the oral bioavailability and stability of a self-emulsifying drug delivery system (SEDDS) of amphotericin B (AmB)."( Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
Bajpai, M; Bhattacharyya, A, 2013
)
0.39
" In conclusion, oral bioavailability of enoxaparin can be enhanced by structure modification of the carriers and the bioavailability is hydrophobic modification degree dependent."( Exploration of hydrophobic modification degree of chitosan-based nanocomplexes on the oral delivery of enoxaparin.
Junyaprasert, VB; Li, C; Li, L; Li, Y; Mao, S; Sun, Y; Tian, Y; Wang, L, 2013
)
0.39
"Present invention relates to design of nanostructured lipid carriers (NLC) to augment oral bioavailability of Carvedilol (CAR)."( Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach.
Bari, SB; Deshmukh, PK; Patil, GB; Patil, ND; Patil, PO, 2016
)
0.43
"Isradipine (ID), is an antihypertensive drug, having low oral bioavailability (15-24%) due to poor aqueous solubility (0."( Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Narendar, D; Swetha, E; Thirupathi, G, 2017
)
0.46
" The in vivo pharmacokinetic study gave many folds increase in oral bioavailability than CC suspension, which was further confirmed by antihypertensive activity in a murine model."( Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Ahmad, FJ; Ali, A; Fazil, M; Hafeez, A; Imam, SS; Khan, S; Paudel, A, 2017
)
0.46
" Nevertheless other compounds as lipids or sugars should be valorized along with polyphenols to improve their bioavailability into highly protected organs as brain or eye."( Characterization, anti-oxidative effect of grape seed powder and in silico affinity profiling of polyphenolic and extra-phenolic compounds for calpain inhibition.
Aouani, E; El Ayed, M; Elkahoui, S; Kadri, S; Limam, F; Mabrouk, M; Mokni, M, 2019
)
0.51
" The anticancer activity of BC through oral administration is severely affected due to its low bioavailability and oxidative degradation."( Beta-carotene-Encapsulated Solid Lipid Nanoparticles (BC-SLNs) as Promising Vehicle for Cancer: an Investigative Assessment.
Ghoshal, G; Jain, A; Katare, OP; Raza, K; Sharma, G; Shivhare, US; Thakur, K, 2019
)
0.51
"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
0.51
"Solid lipid nanoparticles (SLN) were designed with glyceryl monstearate (GMS) in order to improve oral bioavailability of DRD."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
0.51
"These results indicated that dronedarone HCl loaded SLN could potentially be exploited as a delivery system for improving oral bioavailability by minimizing first pass metabolism."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The present study aimed to develop a surface-modified biocompatible nanostructured lipid carrier (NLCs) system using polyoxyethylene (40) stearate (POE-40-S) to improve the oral bioavailability of poorly water-soluble Biopharmaceutics Classification System class-II drug like tamoxifen (TMX)."( Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design:
Damodharan, N; Poovi, G, 2020
)
0.56
"This research aimed to overcome the current challenges in the application of natural carotenoid antioxidants, such as their complex preparation processes, low bioavailability and poor drug stability."( Preparation of astaxanthin micelles self-assembled by a mechanochemical method from hydroxypropyl β-cyclodextrin and glyceryl monostearate with enhanced antioxidant activity.
Polyakov, NE; Su, W; Xu, W, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The results of this study help in understanding the complex solid-state behaviour of solid lipid extrudates with different composition and to manufacture suitable lipid-based oral dosage forms."( Influence of the composition of glycerides on the solid-state behaviour and the dissolution profiles of solid lipid extrudates.
Kleinebudde, P; Strachan, CJ; Windbergs, M, 2009
)
0.35
" The in vivo pharmacodynamic activity revealed 2-fold increase in antimalarial activity of curcuminoids entrapped in lipid nanoparticles when compared to free curcuminoids at the tested dosage level."( Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment.
Madhusudhan, B; Nayak, AP; Patankar, S; Souto, EB; Tiyaboonchai, W, 2010
)
0.36
"To predict drug dissolution and understand the mechanisms of drug release from wax matrix dosage forms containing glyceryl monostearate (GM; a wax base), aminoalkyl methacrylate copolymer E (AMCE; a pH-dependent functional polymer), and acetaminophen (APAP; a model drug), we tried to derive a novel mathematical model with respect to erosion and diffusion theory."( A theoretical approach to evaluate the release rate of acetaminophen from erosive wax matrix dosage forms.
Agata, Y; Itai, S; Iwao, Y; Miyagishima, A; Shiino, K, 2011
)
0.37
"From wax matrix dosage forms, drug and water-soluble polymer are released into the external solvent over time."( A novel mathematical model considering change of diffusion coefficient for predicting dissolution behavior of acetaminophen from wax matrix dosage form.
Agata, Y; Itai, S; Iwao, Y; Nitanai, Y, 2012
)
0.38
" The currently available dosage forms are in the form of tablet."( Fabrication, Characterization, In vitro Evaluation of Solid Lipid Nanoemulsion of Flunarizine dihydrochloride for Nasal Delivery.
Harjot, K; Newton, MJ, 2017
)
0.46
"Antiemetic agent Meclizine HCl, widely prescribed in vertigo, is available only in immediate release dosage forms."( Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
Ahmad, M; Ahmed, K; Nasiri, MI; Qazi, F; Shoaib, MH; Yousuf, RI, 2017
)
0.46
" In view of oral solid dosage forms, various taste masking techniques can be applied encapsulating the active pharmaceutical ingredient (API) to prevent the interaction with the taste buds."( Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
Breitkreutz, J; Münster, M; Schmidt, C; Schoch, C, 2017
)
0.46
" Atenolol is used for cardiovascular diseases and available as an immediate release (IR) tablet dosage form."( Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Ahmed, HF; Hussain, T; Iffat, W; Maboos, M; Nasiri, I; Shoaib, MH; Yousuf, RI, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
Caenorhabditis elegans metaboliteA nematode metabolite produced by Caenorhabditis elegans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1-acylglycerol 18:0A 1-monoglyceride in which the acyl group contains 18 carbons and is fully saturated.
rac-1-monoacylglycerolA racemate that is composed of equal amounts of 1-acyl-sn-glycerol and 3-acyl-sn-glycerol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency4.46680.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency12.61720.000221.22318,912.5098AID1259243; AID743036; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.67500.001022.650876.6163AID1224838
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.44810.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.53530.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.68740.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.09820.000229.305416,493.5996AID743075
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency15.244219.739145.978464.9432AID1159509
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID331221Inhibition of COX2 at 50 uM2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Monoglycerides from the brown alga Sargassum sagamianum: Isolation, synthesis, and biological activity.
AID331222Inhibition of sPLA2-2A at 10 uM by coupled enzyme assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Monoglycerides from the brown alga Sargassum sagamianum: Isolation, synthesis, and biological activity.
AID332270Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds.
AID681134TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells2004British journal of pharmacology, Oct, Volume: 143, Issue:3
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (177)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (2.82)18.7374
1990's4 (2.26)18.2507
2000's56 (31.64)29.6817
2010's89 (50.28)24.3611
2020's23 (12.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.31 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index5.54 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.55%)6.00%
Case Studies4 (2.20%)4.05%
Observational0 (0.00%)0.25%
Other177 (97.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]